6.
Muniyappa R, Montagnani M, Kon Koh K, Quon M
. Cardiovascular actions of insulin. Endocr Rev. 2007; 28(5):463-91.
DOI: 10.1210/er.2007-0006.
View
7.
Hubert H, Feinleib M, MCNAMARA P, CASTELLI W
. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5):968-77.
DOI: 10.1161/01.cir.67.5.968.
View
8.
Samaniyan Bavarsad P, Kheiri S, Ahmadi A
. Estimation of the 10-Year Risk of Cardiovascular Diseases: Using the SCORE, WHO/ISH, and Framingham Models in the Shahrekord Cohort Study in Southwestern Iran. J Tehran Heart Cent. 2021; 15(3):105-112.
PMC: 7827119.
DOI: 10.18502/jthc.v15i3.4219.
View
9.
Santos A, Rodrigues A, Rosa L, Sarrafzadegan N, Silveira E
. Cardiometabolic risk factors and Framingham Risk Score in severely obese patients: Baseline data from DieTBra trial. Nutr Metab Cardiovasc Dis. 2019; 30(3):474-482.
DOI: 10.1016/j.numecd.2019.10.010.
View
10.
Delshad M, Ghanbarian A, Ghaleh N, Amirshekari G, Askari S, Azizi F
. Reliability and validity of the modifiable activity questionnaire for an Iranian urban adolescent population. Int J Prev Med. 2015; 6:3.
PMC: 4362275.
DOI: 10.4103/2008-7802.151433.
View
11.
Mora S, Yanek L, Moy T, Daniele Fallin M, Becker L, Becker D
. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation. 2005; 111(15):1871-6.
DOI: 10.1161/01.CIR.0000161956.75255.7B.
View
12.
Anderson K, Odell P, Wilson P, Kannel W
. Cardiovascular disease risk profiles. Am Heart J. 1991; 121(1 Pt 2):293-8.
DOI: 10.1016/0002-8703(91)90861-b.
View
13.
. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788.
PMC: 6227606.
DOI: 10.1016/S0140-6736(18)32203-7.
View
14.
Khalili D, Sheikholeslami F, Bakhtiyari M, Azizi F, Momenan A, Hadaegh F
. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PLoS One. 2014; 9(8):e105804.
PMC: 4146560.
DOI: 10.1371/journal.pone.0105804.
View
15.
Kim C, Kang H, Schlenk E, Chae S
. Assessment of cardiovascular risk in adults with type 2 diabetes and metabolic syndrome: Framingham versus UKPDS equations. Diabetes Educ. 2015; 41(2):203-13.
DOI: 10.1177/0145721715572154.
View
16.
DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J
. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53.
DOI: 10.1161/CIRCULATIONAHA.107.699579.
View
17.
Teede H, Tay C, Laven J, Dokras A, Moran L, Piltonen T
. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10):2447-2469.
PMC: 10505534.
DOI: 10.1210/clinem/dgad463.
View
18.
Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E
. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020; 18(1):23.
PMC: 7076940.
DOI: 10.1186/s12958-020-00576-1.
View
19.
Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P
. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2019; 395(10226):795-808.
PMC: 8006904.
DOI: 10.1016/S0140-6736(19)32008-2.
View
20.
Berni T, Morgan C, Aled Rees D
. Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab. 2021; 106(9):e3369-e3380.
PMC: 8372630.
DOI: 10.1210/clinem/dgab392.
View